关于卵巢早衰问题的现代观点

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

卵巢早衰综合征是一种复杂的多因素性疾病，其主要临床表现为持续性或间歇性闭经，持续时间不少于四个月。该疾病的诊断年龄通常不超过40岁。本文的重点在于更深入地分析卵巢早衰的病因、发病机制及其主要临床表现。重点在于对年轻及中等生育年龄女性进行该病的早期诊断，从而确定实现生育目标的最优管理方案，并评估当前相关科研工作的进展情况。文中重点探讨了若干相对较新的治疗方法，这些方法已显示出积极的治疗效果，包括富血小板血浆疗法、外泌体治疗、卵泡体外激活、干细胞治疗、微小RNA以及线粒体靶向治疗。这些实验性治疗策略旨在通过增强自然的生物化学通路（新卵泡生成）并改善卵巢微环境，以促进卵母细胞发生和卵泡生成。

全文:

受限制的访问

作者简介

A. I. Tarasova

I.M. Sechenov First Moscow State Medical University

编辑信件的主要联系方式.
Email: tarasova.a.2801@mail.ru
ORCID iD: 0009-0007-7764-7696
俄罗斯联邦, Moscow

M. S. Pervushova

I.M. Sechenov First Moscow State Medical University

Email: masha.pervushova@mail.ru
ORCID iD: 0009-0005-9325-3713
俄罗斯联邦, Moscow

Ya. V. Kirilenko

I.M. Sechenov First Moscow State Medical University

Email: yanchik15320155@gmail.com
ORCID iD: 0009-0004-1512-0707
俄罗斯联邦, Moscow

M. V. Denisenko

MD GROUP Clinical Hospital «Mother and Child»

Email: margarita_pmc@mail.ru
ORCID iD: 0009-0007-7731-5114

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Moscow

E. A. Sosnova

I.M. Sechenov First Moscow State Medical University

Email: sosnova-elena@inbox.ru
ORCID iD: 0000-0002-1732-6870

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow

参考

  1. Tabeyeva GI, Shamilova NN, Zhakhur NF, et al. Premature ovarian failure is an enigma of the 21st century. Akusherstvo i Ginekologiya. 2013;(12):16–21. EDN: RTECLB
  2. Adamyan LV, Menzhinskaya IV, Antonova AA, Tonoyan N.M. Profile of serum autoantibodies in women with premature ovarian insufficiency receiving complex treatment using new surgical technologies. Russian Journal of Human Reproduction. 2024;30(2):32–41. doi: 10.17116/repro20243002132 EDN: BIULUH
  3. Dudareva YuA, Guryeva VA. Antenatal aspects of the formation of reproductive health. Russian Bulletin of Obstetrician-Gynecologist. 2017;17(6):19–24. doi: 10.17116/rosakush201717619-24 EDN: XHJQQP
  4. Strizhakov AN, Pashkov VM, Davydov AI. Nonoperative gynecology: training manual. Moscow: Sechenov University Publishing house; 2023. 335 р. (In Russ.)
  5. Jankowska K. Premature ovarian failure. Prz Menopauzalny. 2017;16(2):51–56. doi: 10.5114/pm.2017.68592
  6. Prasad S, Tiwari M, Pandey AN, et al. Impact of stress on oocyte quality and reproductive outcome. J Biomed Sci. 2016;23:36. doi: 10.1186/s12929-016-0253-4
  7. Chebotnikova TV. Premature ovarian insufficiency: expert opinion. Bulletin of Reproductive Health. 2007;(1):22–32. (In Russ.) EDN: RBAYHZ
  8. Gasparov AS, Dubinskaya ED, Titov DS, Lapteva NV. Clinical value of the ovarian reserve in reproductive function. Akusherstvo i Ginekologiya. 2014;(4):11–16. EDN: SHANRJ
  9. Mauri D, Gazouli I, Zarkavelis G, et al. Chemotherapy associated ovarian failure. Front Endocrinol. 2020;11:572388. doi: 10.3389/fendo.2020.572388
  10. Tkachenko LV, Gritsenko IA, Tikhaeva KYu, et al. Assessment of risk factors and prediction of premature ovarian failure. Obstetrics, Gynecology and Reproduction. 2022;16(1):73–80. doi: 10.17749/2313-7347/ob.gyn.rep.2021.273
  11. Jiang C, Gao T, Wang Y, et al. Birth weight and premature ovarian insufficiency: a systematic review and meta-analysis. Ovarian Res. 2024;17(1):74. doi: 10.1186/s13048-024-01357-9
  12. Clinical recommendations: Galactose metabolism disorders (Galactosemia). 2021–2022–2023 (31.08.2021). Approved by the Ministry of Health of the Russian Federation. Moscow; 2024. (In Russ.)
  13. Samoilovich YaA. Ovarian follicle aromatase p450 deficiency in normogonadotropic anovulation [dissertation]. Saint-Petersburg; 2016. 134 р. (In Russ.) EDN: VBHFOU
  14. Tsolin VA. Dynamic sofindicesofimmun. International Journal of Advanced Studies in Medicine and Biomedical Sciences. 2019;(1):102–105. EDN: ZSEBML
  15. Shamilova NN, Marchenko LA, Dolgushina NV, et al. Role of genetic and autoimmune disorders in the development of premature ovarian failure. Akusherstvo i Ginekologiya. 2012;(4-2):67–72. EDN: PIDMUV
  16. Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an international menopause society white paper. Climacteric. 2020;23(5):426–446. doi: 10.1080/13697137.2020.1804547
  17. Ates S, Aydın S, Ozcan P, et al. Sleep, depression, anxiety and fatigue in women with premature ovarian insufficiency. J Psychosom Obstet Gynaecol. 2022;43(4):482–487. doi: 10.1080/0167482X.2022.2069008
  18. Blinov DV, Hasan PL, Mnatsakanyan AN, et al. Early menopause and premature ovarian insufficiency: problems and perspectives. Obstetrics, Gynecology and Reproduction. 2020;14(3):328–345. doi: 10.17749/2313-7347/ob.gyn.rep.2020.173 EDN: YOYBIN
  19. Averkova VG, Donnikov AE. Premature ovarian insufficiency: long-term health consequences and hormone replacement therapy strategies. Doctor.Ru. 2023;22(5):49–53. doi: 10.31550/1727-2378-2023-22-5-49-53 EDN: WCILCY
  20. van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update. 1999;5(5):483–492. doi: 10.1093/humupd/5.5.483
  21. Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937. doi: 10.1093/humrep/dew027
  22. Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106(7):1588–1599. doi: 10.1016/j.fertnstert.2016.09.046
  23. Koroleva V. Guide to managing patients with premature ovarian failure. How to assess, treat and allay patients’ fears: a quick guide. Practicing Gynecologist. 2025;(1):6. (In Russ.)
  24. Adamyan LV, Sibirskaya EV, Shcherina AV. Pathogenetic aspects of premature ovarian failure. Russian Journal of Human Reproduction. 2021;27(1):6–12. doi: 10.17116/repro2021270116 EDN: DACUOQ
  25. Naimi ZMS, Kalinina EA, Donnikov AE, et al. Role of vitamin D in the outcomes of assisted reproductive technology programs. Akusherstvo i Ginekologiya. 2015;(11):5–10. EDN: VAXPMN
  26. Patent RUS № 2750159 / 22.06.2021. Byul. № 18. Mashaeva RI, Marchenko LA, Olimpieva SP, et al. Method for diagnosis of premature ovarian insufficiency. Available from: https://www.elibrary.ru/download/elibrary_46316397_60967996.PDF (In Russ.) EDN: AHDTWN
  27. Yupatov EYu, Kurmanbaev TE, Shmidt AA, et al. Cryopreservation of reproductive tissue — the possibility of preserving fertility (a review). Russian Journal of Human Reproduction. 2020;26(5):99–106. doi: 10.17116/repro20202605199 EDN: UCZHBN
  28. Abdulaeva AS, Kuzmina PI, Bakhtiyarov KR. Possibilities of reproductive function realization in patients with premature ovarian insufficiency. Medical Council. 2024;18(4):30–36. doi: 10.21518/ms2024-126 EDN: IAESPI
  29. Xu YP, Fu JC, Hong ZL, et al. Psychological stressors involved in the pathogenesis of premature ovarian insufficiency and potential intervention measures. Gynecol Endocrinol. 2024;40(1):2360085. doi: 10.1080/09513590.2024.2360085
  30. Radzinsky VE, Ordiyants IM, Pobedinskaya OS. Modern technologies in treatment of patients with premature ovarian failure. Obstetrics and Gynecology. News. Views. Education. 2015;(3):123–136. EDN: VNTCIB
  31. Shikh EV. Comparative clinical pharmacological aspects of oral and transdermal dosage forms of estrogens. Obstetrics and Gynecology. News. Views. Education. 2016;(1):41–46. EDN: VQZJGH
  32. Adamyan LV, Alyasova AV, Mailova KS, Stepanyan A.A. Non-hormonal methods of treating premature ovarian insufficiency (POI). Russian Journal of Human Reproduction. 2024;30(2):6–14. doi: 10.17116/repro2024300216 EDN: GTVEXP
  33. Sfakianoudis K, Simopoulou M, Grigoriadis S, et al. Reactivating ovarian function through autologous platelet-rich plasma intraovarian infusion: pilot data on premature ovarian insufficiency, perimenopausal, menopausal, and poor responder women. J Clin Med. 2020;9(6):1809. doi: 10.3390/jcm9061809
  34. Hosseini L, Shirazi A, Naderi MM, et al. Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. Reprod Biomed Online. 2017;35(4):343–350. doi: 10.1016/j.rbmo.2017.04.007
  35. He F, Liu Y, Li T, et al. MicroRNA-146 attenuates lipopolysaccharide induced ovarian dysfunction by inhibiting the TLR4/NF-κB signaling pathway. Bioengineered. 2022;13(5):11611–11623. doi: 10.1080/21655979.2022.2070584
  36. Vitti Labs, LLC. A proof of concept study to evaluate exosomes from human mesenchymal stem cells in women with premature ovarian insufficiency (POI) (VL-POI-01). US Clinical Trials Registry. Clinical Trial NCT06072794. 2024 Sep.
  37. Huang QY, Chen SR, Chen JM, et al. Therapeutic options for premature ovarian insufficiency: an updated review. Reprod Biol Endocrinol. 2022;20(1):28. doi: 10.1186/s12958-022-00892-8
  38. Apolikhina IA, Saidova AS, Baranov II. Use of placental therapy in the correction of functional impairments in women: investigations and clinical practice. Akusherstvo i Ginekologiya. 2020;(3):203–210. doi: 10.18565/aig.2020.3.203-210 EDN: QFPOJB
  39. Savelyeva GM, Sukhykh GT, Manukhin IB, et al. Gynecology: national guidelines. Moscow: GEOTAR-Media Publ.; 2015, 704 p. (In Russ.) ISBN: 978-5-9704-3217-4
  40. Patent RUS № 2748246 / 21.05.2021. Byul. № 15. Adamyan LV, Smolnikova VYu, Asaturova AV, et al. One-step surgical method of ovarian function activation for treatment of premature ovarian insufficiency and restoration of ovarial function. Available from: https://www.elibrary.ru/download/elibrary_45812844_32988564.PDF (In Russ.) EDN: DZMHLN

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2025


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86335 от 11.12.2023 г.  
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80633 от 15.03.2021 г.